Safety and Efficacy Study of Serostim® Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome

PHASE3CompletedINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

January 31, 2006

Study Completion Date

January 31, 2006

Conditions
Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome
Interventions
BIOLOGICAL

Serostim

Serostim® 4 mg daily given for 12 weeks (following a prior 36-week treatment \[Serono Study 24380\] with Serostim® 4 mg daily given for 12 weeks, followed by 24-weeks of either Serostim® 2 mg every other day or Placebo every other day)

Trial Locations (26)

Unknown

University of Alabama/Birmingham, Birmingham

Care Clinic, Los Angeles

Private Practice, Palm Beach

UCSD - AVRC (AntiViralResearchCenter), San Diego

Kaiser Permanente, San Francisco

Harbor-UCLA Medical Center, Torrence

AIDS Alliance, West Hollywood

Circle Medical LLC, Norwalk

Private Practice, Washington D.C.

Private Practice, Fort Lauderdale

Care Resources, Miami

Private Practice, Miami

Private Practice, North Miami Beach

Infectious Disease Associates, Sarasota

AIDS Research Consortium of Atlanta, Atlanta

Rush University Medical Center, Chicago

Community Research Initiative of New England, Boston

Tufts University School of Medicine, Boston

Hennepin County Medical Center, Minneapolis

St. Luke's Roosevelt Hospital, New York

St. Vincents Catholic Medical Center, New York

Weill Medical College of Cornell University, New York

Central Texas Clinical Research, Austin

IPD Research, Annandale

Private Practice, Spokane

St Paul Hospital, Vancouver

Sponsors

Lead Sponsor

All Listed Sponsors
lead

EMD Serono

INDUSTRY

NCT01077960 - Safety and Efficacy Study of Serostim® Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome | Biotech Hunter | Biotech Hunter